US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cardiovascular

20.00

0.0000

Volume:- -

Turnover:- -

Market Cap:843.96M

PE:-20.84

High:20.00

Open:20.00

Low:20.00

Close:20.00

52wk High:23.47

52wk Low:12.26

Shares:42.20M

Float Shares:40.69M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9598

EPS(LYR):-0.9415

ROE:-15.18%

ROA:-7.56%

PB:3.53

PE(LYR):-21.24

Loading ...

Overview Company News Filings

Artrya Says US Health System Agrees to In-Principle Participation in Cardiovascular Study

MT Newswires Live

Press Release: Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

Is Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?

Simply Wall St.

Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction

Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug

MT Newswires Live

White House Says Trump's MRI Was to Screen Cardiovascular Health -- WSJ

Avricore Health’s HealthTab Expands Role in NHS Cardiovascular Care Pilot

This Medical Device Maker Is Seeing High Demand In Cardiovascular, Diabetes Business

Acotec Scientific Gains Approval for New Cardiovascular Device

Amgen (AMGN) Is Up 5.6% After Repatha Phase 3 Trial Shows Cardiovascular Benefits – Has The Bull Case Changed?

Simply Wall St.

CRISPR Therapeutics (CRSP): Assessing Valuation Following Promising Early CTX310 Cardiovascular Trial Results

Simply Wall St.

Amgen Says Repatha Significantly Reduces Risk of Cardiovascular Event in Phase 3 Study

MT Newswires Live

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

King-Friend Biochemical Pharmaceutical Passes Drug Consistency Evaluation for Cardiovascular Drug

MT Newswires Live

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment

Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSII/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CSII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","market":"US","secType":"STK","nameCN":"Cardiovascular","latestPrice":20,"timestamp":1688155200000,"preClose":20,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":40687277,"shares":42198048,"eps":-0.959831,"marketStatus":"Market Closed","change":0,"latestTime":"06-30 16:00:00 EDT","open":20,"high":20,"low":20,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.959831,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1151467200000,"exchange":"NASDAQ","adjPreClose":20,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","floatShares":40687277,"roa":"-7.56%","roe":"-15.18%","lyrEps":-0.941454,"shares":42198048,"dividePrice":0,"high":20,"amplitude":0,"preClose":20,"low":20,"week52Low":12.255,"pbRate":"3.53","psRate":"3.52","week52High":23.47,"institutionHeld":0.4085,"latestPrice":20,"eps":-0.959831,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.959831,"open":20,"prevYearClose":13.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSII\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-04-28","symbol":"CSII","reason":null,"defaultRemindTime":1682688600000,"announcedDate":"2023-04-27","type":"delisting","dateTimestamp":1682654400000},{"date":"2023-02-09","symbol":"CSII","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2022/12","expectedEps":-0.15,"defaultRemindTime":1675933200000,"name":null,"time":"Pre-Market","dateTimestamp":1675918800000,"actualEps":null},{"market":"US","date":"2022-08-02","symbol":"CSII","fiscalQuarterEnding":"2022/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659412800000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2022-05-04","symbol":"CSII","fiscalQuarterEnding":"2022/03","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1651636800000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2021-11-09","symbol":"CSII","fiscalQuarterEnding":"2021/09","expectedEps":-0.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1636434000000,"reportTimeType":"pre","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSII\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.6667,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":6,"updateTime":1676001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSII\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSII","date":"2023-04-26","current":-20.837002,"percent":0.602228,"low":-7142.134596,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"high":1513.025574,"avg":-244.968737,"sd":1483.721277,"marketCap":843538979},"quantilePoints":[{"date":"2021-02-12","current":-86.328944,"twenty":-223.145513,"median":-21.265484,"eighty":649.10488,"marketCap":1742722388},{"date":"2021-02-19","current":-82.685448,"twenty":-223.145513,"median":-21.492549,"eighty":649.10488,"marketCap":1669171143},{"date":"2021-02-26","current":-82.227523,"twenty":-223.145513,"median":-21.598052,"eighty":649.10488,"marketCap":1659926998},{"date":"2021-03-05","current":-80.117082,"twenty":-223.323098,"median":-21.772834,"eighty":649.309001,"marketCap":1617323544},{"date":"2021-03-12","current":-83.461931,"twenty":-223.323098,"median":-21.854907,"eighty":649.309001,"marketCap":1684845999},{"date":"2021-03-19","current":-80.435639,"twenty":-223.323098,"median":-21.959778,"eighty":649.309001,"marketCap":1623754254},{"date":"2021-03-26","current":-77.787635,"twenty":-223.145513,"median":-22.077677,"eighty":649.10488,"marketCap":1570298978},{"date":"2021-04-01","current":-74.442786,"twenty":-223.145513,"median":-22.365875,"eighty":649.10488,"marketCap":1502776524},{"date":"2021-04-09","current":-71.93415,"twenty":-223.323098,"median":-22.46194,"eighty":649.309001,"marketCap":1452134683},{"date":"2021-04-16","current":-77.608446,"twenty":-223.323098,"median":-22.539344,"eighty":649.309001,"marketCap":1566681704},{"date":"2021-04-23","current":-81.072753,"twenty":-223.323098,"median":-22.783943,"eighty":649.309001,"marketCap":1636615674},{"date":"2021-04-30","current":-80.276361,"twenty":-223.145513,"median":-22.907337,"eighty":649.10488,"marketCap":1620538899},{"date":"2021-05-07","current":-61.125515,"twenty":-223.145513,"median":-23.047069,"eighty":649.10488,"marketCap":1424346748},{"date":"2021-05-14","current":-62.685323,"twenty":-223.145513,"median":-23.118044,"eighty":649.10488,"marketCap":1460693394},{"date":"2021-05-21","current":-66.40818,"twenty":-223.145513,"median":-23.448954,"eighty":649.10488,"marketCap":1547443401},{"date":"2021-05-28","current":-67.545719,"twenty":-223.145513,"median":-23.542167,"eighty":649.10488,"marketCap":1573950347},{"date":"2021-06-04","current":-65.701526,"twenty":-223.145513,"median":-23.665911,"eighty":649.10488,"marketCap":1530976964},{"date":"2021-06-11","current":-68.131724,"twenty":-223.145513,"median":-23.842011,"eighty":649.10488,"marketCap":1587605441},{"date":"2021-06-18","current":-71.802875,"twenty":-223.145513,"median":-23.92517,"eighty":649.10488,"marketCap":1673150586},{"date":"2021-06-25","current":-75.887676,"twenty":-222.967928,"median":-24.312681,"eighty":648.900759,"marketCap":1768334621},{"date":"2021-07-02","current":-73.526419,"twenty":-222.967928,"median":-24.606789,"eighty":648.900759,"marketCap":1713312626},{"date":"2021-07-09","current":-74.112425,"twenty":-222.967928,"median":-44.751281,"eighty":648.900759,"marketCap":1726967720},{"date":"2021-07-16","current":-62.874913,"twenty":-222.967928,"median":-46.066945,"eighty":648.900759,"marketCap":1465111219},{"date":"2021-07-23","current":-67.631896,"twenty":-222.967928,"median":-46.851785,"eighty":648.900759,"marketCap":1575958449},{"date":"2021-07-30","current":-69.441618,"twenty":-222.967928,"median":-47.492643,"eighty":648.900759,"marketCap":1618128591},{"date":"2021-08-06","current":-116.556997,"twenty":-222.967928,"median":-48.109035,"eighty":648.900759,"marketCap":1564311458},{"date":"2021-08-13","current":-107.938662,"twenty":-222.967928,"median":-49.469834,"eighty":648.900759,"marketCap":1448644782},{"date":"2021-08-20","current":-109.829981,"twenty":-222.967928,"median":-51.159368,"eighty":648.900759,"marketCap":1474028176},{"date":"2021-08-27","current":-105.995219,"twenty":-222.967928,"median":-52.039983,"eighty":648.900759,"marketCap":1422561835},{"date":"2021-09-03","current":-108.212191,"twenty":-222.948196,"median":-53.089223,"eighty":648.898305,"marketCap":1452315813},{"date":"2021-09-10","current":-105.605751,"twenty":-222.948196,"median":-54.352435,"eighty":648.898305,"marketCap":1417334784},{"date":"2021-09-17","current":-109.620267,"twenty":-222.948196,"median":-55.22172,"eighty":648.898305,"marketCap":1471213610},{"date":"2021-09-24","current":-99.883567,"twenty":-222.948196,"median":-55.619529,"eighty":648.898305,"marketCap":1340537353},{"date":"2021-10-01","current":-102.201456,"twenty":-222.948196,"median":-56.577216,"eighty":648.898305,"marketCap":1371645743},{"date":"2021-10-08","current":-97.96826,"twenty":-222.928465,"median":-58.230986,"eighty":648.895851,"marketCap":1314832014},{"date":"2021-10-15","current":-101.354817,"twenty":-222.928465,"median":-59.228611,"eighty":648.895851,"marketCap":1360282997},{"date":"2021-10-22","current":-102.443353,"twenty":-222.928465,"median":-60.207213,"eighty":648.895851,"marketCap":1374892241},{"date":"2021-10-29","current":-106.071807,"twenty":-222.928465,"median":-61.050012,"eighty":648.895851,"marketCap":1423589723},{"date":"2021-11-05","current":-107.281292,"twenty":-222.928465,"median":-61.439537,"eighty":648.895851,"marketCap":1439822217},{"date":"2021-11-12","current":-55.251112,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":1102977952},{"date":"2021-11-19","current":-46.597813,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":930232140},{"date":"2021-11-26","current":-47.247826,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":943208351},{"date":"2021-12-03","current":-38.574214,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":770057033},{"date":"2021-12-10","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2021-12-17","current":-38.371085,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":766001967},{"date":"2021-12-23","current":-40.341437,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":805336107},{"date":"2021-12-31","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2022-01-07","current":-36.847617,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":735588972},{"date":"2022-01-14","current":-38.960159,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":777761658},{"date":"2022-01-21","current":-36.705426,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":732750426},{"date":"2022-01-28","current":-34.999142,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":698687871},{"date":"2022-02-04","current":-24.987669,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":721493944},{"date":"2022-02-11","current":-26.786556,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":773435015},{"date":"2022-02-18","current":-26.449265,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":763696064},{"date":"2022-02-25","current":-29.765963,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":859462415},{"date":"2022-03-04","current":-30.819998,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":889896636},{"date":"2022-03-11","current":-25.943327,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":749087638},{"date":"2022-03-18","current":-29.147595,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":841607671},{"date":"2022-03-25","current":-29.077326,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":839578723},{"date":"2022-04-01","current":-32.801585,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":947112973},{"date":"2022-04-08","current":-30.637299,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":884621371},{"date":"2022-04-14","current":-30.257846,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":873665051},{"date":"2022-04-22","current":-29.021111,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":837955565},{"date":"2022-04-29","current":-26.280619,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":758826589},{"date":"2022-05-06","current":-19.196392,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":624420233},{"date":"2022-05-13","current":-19.986315,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":650114860},{"date":"2022-05-20","current":-19.572546,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":636655770},{"date":"2022-05-27","current":-20.161854,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":655824777},{"date":"2022-06-03","current":-20.099161,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":653785521},{"date":"2022-06-10","current":-18.55693,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":603619820},{"date":"2022-06-17","current":-17.227853,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":560387590},{"date":"2022-06-24","current":-18.770084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":610553291},{"date":"2022-07-01","current":-18.268545,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594239242},{"date":"2022-07-08","current":-18.694853,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":608106183},{"date":"2022-07-15","current":-19.033392,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":619118167},{"date":"2022-07-22","current":-19.998854,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":650522711},{"date":"2022-07-29","current":-19.321776,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":628498745},{"date":"2022-08-05","current":-18.27617,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":674993785},{"date":"2022-08-12","current":-18.375557,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":678664446},{"date":"2022-08-19","current":-16.803903,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620618538},{"date":"2022-08-26","current":-15.495084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":572279932},{"date":"2022-09-02","current":-14.530107,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":536640452},{"date":"2022-09-09","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-16","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-23","current":-14.341549,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":529676415},{"date":"2022-09-30","current":-15.726213,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":580816217},{"date":"2022-10-07","current":-14.568872,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":538072166},{"date":"2022-10-14","current":-14.70503,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":543100878},{"date":"2022-10-21","current":-15.828331,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":584587751},{"date":"2022-10-28","current":-16.804128,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620626852},{"date":"2022-11-04","current":-15.356608,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":598078472},{"date":"2022-11-11","current":-15.776012,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":614412548},{"date":"2022-11-18","current":-15.496409,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":603523164},{"date":"2022-11-25","current":-15.270577,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594727893},{"date":"2022-12-02","current":-14.980221,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":583419686},{"date":"2022-12-09","current":-14.453279,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":562897386},{"date":"2022-12-16","current":-15.603949,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":607711389},{"date":"2022-12-23","current":-14.324231,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":557871516},{"date":"2022-12-30","current":-14.646849,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":570436190},{"date":"2023-01-06","current":-15.410378,"twenty":-221.981345,"median":-61.14502,"eighty":648.893398,"marketCap":600172585},{"date":"2023-01-13","current":-15.055498,"twenty":-220.996594,"median":-60.343621,"eighty":648.893398,"marketCap":586351444},{"date":"2023-01-20","current":-14.732881,"twenty":-218.210257,"median":-59.815039,"eighty":648.893398,"marketCap":573786770},{"date":"2023-01-27","current":-14.388755,"twenty":-216.298622,"median":-58.757875,"eighty":648.893398,"marketCap":560384451},{"date":"2023-02-03","current":-15.829781,"twenty":-213.098642,"median":-57.579104,"eighty":648.893398,"marketCap":616506661},{"date":"2023-02-10","current":-21.828798,"twenty":-209.864261,"median":-56.194141,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-17","current":-21.828798,"twenty":-206.639894,"median":-55.413615,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-24","current":-21.828798,"twenty":-204.396855,"median":-55.251112,"eighty":648.893398,"marketCap":826591078},{"date":"2023-03-03","current":-21.928523,"twenty":-200.181145,"median":-54.89758,"eighty":648.893398,"marketCap":830367383},{"date":"2023-03-10","current":-21.69583,"twenty":-195.294526,"median":-53.276878,"eighty":648.893398,"marketCap":821556006},{"date":"2023-03-17","current":-22.020055,"twenty":-191.11887,"median":-52.525462,"eighty":648.893398,"marketCap":833833428},{"date":"2023-03-24","current":-22.109205,"twenty":-188.575425,"median":-51.759312,"eighty":648.893398,"marketCap":837209272},{"date":"2023-03-31","current":-22.131493,"twenty":-184.820339,"median":-51.013718,"eighty":648.890944,"marketCap":838053233},{"date":"2023-04-06","current":-22.164924,"twenty":-177.300152,"median":-49.651896,"eighty":648.893398,"marketCap":839319174},{"date":"2023-04-14","current":-22.24293,"twenty":-171.241947,"median":-48.700677,"eighty":648.895851,"marketCap":842273038},{"date":"2023-04-21","current":-22.265218,"twenty":-159.435956,"median":-47.656498,"eighty":648.895851,"marketCap":843116999},{"date":"2023-04-26","current":-22.276361,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"marketCap":843538979}],"updateTime":1770441510454},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSII\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608827108","title":"Artrya Says US Health System Agrees to In-Principle Participation in Cardiovascular Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2608827108","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608827108?lang=en_us&edition=fundamental","pubTime":"2026-02-02 07:32","pubTimestamp":1769988773,"startTime":"0","endTime":"0","summary":"Artrya  said Dignity Health Arizona agreed to in-principle participation in the retrospective US multi-center SAPPHIRE Study, according to a Monday filing with the Australian bourse.The study will evaluate the clinical and prognostic value of the Salix plaque analysis and its plaque dispersion score to identify patients at elevated risk of cardiovascular events, the filing said.Additionally, the company plans to focus its upcoming study on women with coronary artery disease, which will include a group of women-only patients at risk, known as SAPPHIRE-WIN, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSII","BK4082","BK7094","AYA.AU"],"gpt_icon":0},{"id":"2606816437","title":"Press Release: Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2606816437","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606816437?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:30","pubTimestamp":1769517000,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 27, 2026  -- Lexeo Therapeutics, Inc. , a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company's continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.Narinder Bhalla, MD has been appointed Chief Medical Officer, effective immediately. With more than two decades of experience as an interventional cardiologist and nearly a decade in biopharma leadership, Dr. Bhalla is a seasoned physician-executive who has held senior roles at AstraZeneca and, most recently, at Bristol Myers Squibb, where he served as Senior Vice President and Head of Global Medical, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4130","LXEO","R","FA","BK4505","BK4539","BK4585","IE0009354923.USD","BK4082","BK4588","RNA","BK4535","BK4139","BK4232","CSII","BK4022"],"gpt_icon":0},{"id":"2606208954","title":"Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2606208954","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606208954?lang=en_us&edition=fundamental","pubTime":"2026-01-27 14:37","pubTimestamp":1769495820,"startTime":"0","endTime":"0","summary":"DAVOS, Switzerland, Jan. 27, 2026 /PRNewswire/ -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, the Ministry of Health of Brunei Darussalam, and EVYD Technology will jointly implement an AI- and data-enabled national cardiovascular disease prevention initiative under the global program: CARDIO4Cities.Mrs. Gong Yingying, Founder and Chairlady of Yidu Tech, speaks with Mr. Marnix van Ginneken, Chairman of the Philips Foundation, during a Davos dialogue on the future of AI-enabled public health. Built on Brunei's national health platform, the program aims to harness population-scale data and artificial intelligence to enable early identification of high-risk individuals and deliver targeted interventions, ultimately reducing cardiovascular disease burden and strengthening national heart health outcomes.This landmark collaboration, recognized for bot","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2870232/Mrs__Gong_Yingying__Founder_and_Chairlady_of_Yidu_Tech__speaks_with_Mr__Marnix_van_Ginneken__Chairma.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2870232/Mrs__Gong_Yingying__Founder_and_Chairlady_of_Yidu_Tech__speaks_with_Mr__Marnix_van_Ginneken__Chairma.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/davos-spotlight--evyd-ministry-of-health-brunei-darussalam-and-novartis-foundation-launch-national-ai-powered-cardiovascular-disease-prevention-initiative-302670872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4587","AI","BK4082","BK4528","CSII","NHLD","BK4551","BK4543","BK4588","BK4585"],"gpt_icon":0},{"id":"2602545704","title":"BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2602545704","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602545704?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226400,"startTime":"0","endTime":"0","summary":"First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216965/0/en/BioAge-Announces-Additional-Positive-Interim-Phase-1-Data-for-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor-Demonstrating-Potential-for-Best-in-Class-hsCRP-Reduction-in-Participa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII"],"gpt_icon":0},{"id":"2602155255","title":"Is Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602155255","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602155255?lang=en_us&edition=fundamental","pubTime":"2026-01-11 23:19","pubTimestamp":1768144745,"startTime":"0","endTime":"0","summary":"In early January 2026, Daiichi Sankyo Europe announced an agreement for Organon to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway, targeting patients with high cholesterol and elevated cardiovascular disease risk who are not well served by statins.\nThis commercialization deal adds a differentiated cardiovascular product to Organon’s portfolio in key European markets, expanding its role in addressing high unmet need among statin-intolerant...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065171402.SGD","LU2065169927.USD","BK4585","BK4588","CSII","BK4082","LU2065170008.USD","BK4559","OGN","LU2065171311.SGD","BK4007"],"gpt_icon":0},{"id":"2592990193","title":"Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990193","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990193?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976400,"startTime":"0","endTime":"0","summary":"SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human Research Ethics Committee , advancing the company's first bi-valent siRNA into clinical development. The Phase 1 trial is expected to begin dosing in Q1 2026.RN5681 is a GalNAc-conjugated, dual-targeting siRNA designed to simultaneously silence both PCSK9 and LPA, two genetically validated and complementary drivers of atherosclerotic cardiovascular disease. By unifying LDL-C lowering and Lp reduction within a single molecule, RN5681 aims to deliver deep, durable lipid improvement and address persistent residual risk not resolved by current therapies.\"As a clinician who has helped bring lipid-lowering therapies to patients, I see exceptional promise in a bi-valent siRNA approach,\" said Alex DePaoli, MD, CMO. \"RN5681 has the potential to expand the treatment paradigm by tackling two of the ","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2845384/Rona_Therapeutics_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2845384/Rona_Therapeutics_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rona-therapeutics-unveils-the-global-first-bi-valent-pcsk9-lpa-sirna-into-clinical-development-for-cardiovascular-risk-reduction-302644452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LPA","BK4539","BK4233","BK4139","BK4007","CSII","BK4082","LENZ"],"gpt_icon":0},{"id":"2590571939","title":"Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571939","media":"MT Newswires Live","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590571939?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:43","pubTimestamp":1765528996,"startTime":"0","endTime":"0","summary":"Shanghai Shyndec Pharmaceutical  subsidiary Sinopharm Rongsheng obtained drug registration for bumetanide injection issued by China's medical products administrator.The drug is used to treat edema associated with conditions such as heart failure and hypertension, according to a Friday filing with the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","600420","BK0132","BK0010","CSII","BK0239","BK0020","BK0082"],"gpt_icon":0},{"id":"2588770724","title":"White House Says Trump's MRI Was to Screen Cardiovascular Health -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2588770724","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588770724?lang=en_us&edition=fundamental","pubTime":"2025-12-02 04:17","pubTimestamp":1764620220,"startTime":"0","endTime":"0","summary":"WASHINGTON -- The White House said President Trump underwent advanced imaging in October to assess his \"cardiovascular and abdominal health,\" offering some new details about the procedure amid increasing pressure to explain why it was necessary.The magnetic resonance imaging, or MRI, was preventive, and doctors found \"no evidence of arterial narrowing impairing blood flow\" or abnormalities in his heart or major vessels, said Navy Capt. Sean Barbabella, Trump's physician, in a memo released by the White House press office.The president's heart chambers are \"normal in size,\" blood vessel walls \"appear smooth and healthy\" and there were no signs of \"inflammation or clotting,\" according to the memo. He cast the screening as typical for a patient of Trump's age.Trump, who is 79 years old, is the oldest man to take the presidential oath of office. His predecessor, Joe Biden, was 81 years old when he dropped his re-election bid last year amid questions about his health and mental acuity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2586714402","title":"Avricore Health’s HealthTab Expands Role in NHS Cardiovascular Care Pilot","url":"https://stock-news.laohu8.com/highlight/detail?id=2586714402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586714402?lang=en_us&edition=fundamental","pubTime":"2025-11-28 09:32","pubTimestamp":1764293566,"startTime":"0","endTime":"0","summary":"Avricore Health ( ($TSE:AVCR) ) has provided an update. Avricore Health’s HealthTab platform is being utilized in a new pilot program by Barts Heal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/avricore-healths-healthtab-expands-role-in-nhs-cardiovascular-care-pilot?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/avricore-healths-healthtab-expands-role-in-nhs-cardiovascular-care-pilot?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","CSII"],"gpt_icon":0},{"id":"2584295828","title":"This Medical Device Maker Is Seeing High Demand In Cardiovascular, Diabetes Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2584295828","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584295828?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:58","pubTimestamp":1763474325,"startTime":"0","endTime":"0","summary":"Medtronic reports strong Q2 2026 results with sales of around $9 billion, surpassing estimates. Organic growth at 5.5%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48921968/this-medical-device-maker-is-seeing-high-demand-in-cardiovascular-diabetes-business","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","IE00BQXX3C00.GBP","LU0314106906.USD","LU1061106388.HKD","LU1244550577.SGD","LU0211326839.USD","LU0158827948.USD","LU0162691827.USD","LU1244550494.USD","BK4585","BK4588","CSII","IE00BFXG1179.USD","LU1506573853.SGD","LU0432979614.USD","LU2089984988.USD","LU2028103732.USD","LU1116320901.HKD","LU0208291251.USD","LU0211326755.USD","BK4082","LU0265550946.USD","LU0976567544.SGD","LU1989764664.SGD","LU1244550221.USD","LU2112291526.USD","LU1571399168.USD","LU1057294990.SGD","LU0211331839.USD","LU1291159041.SGD","LU0072461881.USD","LU2023251221.USD","LU2271345857.HKD","BK4566","LU0122379950.USD","LU1983299246.USD","LU1989764748.USD","LU1116320737.USD","LU0070302665.USD","LU2468319806.SGD","IE00BQXX3D17.EUR","LU1023059063.AUD","LU0158827781.USD","MDT","IE00BQXX3F31.USD","LU0265550359.USD","LU0496365809.HKD","LU1989771016.USD","BK4533","LU2111349929.HKD"],"gpt_icon":0},{"id":"2584893534","title":"Acotec Scientific Gains Approval for New Cardiovascular Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2584893534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584893534?lang=en_us&edition=fundamental","pubTime":"2025-11-18 18:07","pubTimestamp":1763460474,"startTime":"0","endTime":"0","summary":"The latest update is out from Acotec Scientific Holdings Limited ( ($HK:6669) ). Acotec Scientific Holdings Limited announced that it has received ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acotec-scientific-gains-approval-for-new-cardiovascular-device?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acotec-scientific-gains-approval-for-new-cardiovascular-device?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2584986740","title":"Amgen (AMGN) Is Up 5.6% After Repatha Phase 3 Trial Shows Cardiovascular Benefits – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584986740","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584986740?lang=en_us&edition=fundamental","pubTime":"2025-11-18 10:24","pubTimestamp":1763432658,"startTime":"0","endTime":"0","summary":"Earlier this month, Amgen announced detailed results from its Phase 3 VESALIUS-CV clinical trial, showing that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events in high-risk adults without a prior heart attack or stroke, when added to statins or other LDL-C-lowering treatments.\nThis marks the first large trial to demonstrate a benefit for LDL-C lowering therapy in high-risk adults who have not yet experienced...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-is-up-56-after-repatha-phase-3-trial-shows-cardio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-is-up-56-after-repatha-phase-3-trial-shows-cardio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1023059063.AUD","BK4585","IE00BFTCPJ56.SGD","LU2112291526.USD","LU0109394709.USD","LU1983299246.USD","LU2242646821.SGD","LU1061106388.HKD","BK4581","LU0889565916.HKD","LU0868494617.USD","BK4082","LU0289739699.SGD","LU2089984988.USD","CSII","LU0320765992.SGD","LU2242652126.USD","BK4599","AMGN","LU0058720904.USD","LU1057294990.SGD","SG9999001440.SGD","IE00B4R5TH58.HKD","BK4566","BK4534","IE0002141913.USD","IE00B2B36J28.USD","BK4533","LU0122379950.USD","BK4588","BK4139","LU1571399168.USD","IE0009355771.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2583552100","title":"CRISPR Therapeutics (CRSP): Assessing Valuation Following Promising Early CTX310 Cardiovascular Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583552100","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583552100?lang=en_us&edition=fundamental","pubTime":"2025-11-13 13:26","pubTimestamp":1763011586,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (NasdaqGM:CRSP) drew investor attention after unveiling early data from its Phase 1 CTX310 trial. The results revealed strong, lasting reductions in cardiovascular risk factors and a safety profile that supports ongoing development.\nSee our latest analysis for CRISPR Therapeutics.\nDespite the buzz around CRISPR Therapeutics’ positive CTX310 trial results and solid progress in its gene-editing pipeline, the share price has pulled back sharply this month, down 23.6% in the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-assessing-valuation-following-promi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-assessing-valuation-following-promi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4082","BK4585","BK4588","BK4139","BK4556","CRSP","CSII","LU1861559042.SGD","LU1861558580.USD","BK4611"],"gpt_icon":0},{"id":"2582873305","title":"Amgen Says Repatha Significantly Reduces Risk of Cardiovascular Event in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873305","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873305?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:01","pubTimestamp":1762776067,"startTime":"0","endTime":"0","summary":"Amgen  said Saturday that Repatha in combination with cholesterol-lowering treatments showed \"statistically significant and clinically meaningful reductions\" in major adverse cardiovascular events in high-risk adults without a prior heart attack or stroke in a phase 3 clinical trial.The study of more than 12,000 patients with atherosclerosis or diabetes showed that the Repatha addition reduced the risk of a composite of coronary heart disease death, heart attack or ischemic stroke by 25% and the risk of heart attack by 36%.The Repatha addition also \"significantly\" reduced the risk of most secondary endpoints, the company said.Results also showed a reduction in the risk of cardiovascular events in nearly 60% of patients in the trial with diabetes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0122379950.USD","LU2242652126.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","LU0868494617.USD","LU1023059063.AUD","BK4581","LU0320765992.SGD","LU1571399168.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","BK4599","LU2242646821.SGD","BK4139","BK4534","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","LU2089984988.USD","LU1983299246.USD","BK4585","LU0289739699.SGD","BK4082","LU1061106388.HKD","CSII","BK4588","LU0058720904.USD","AMGN","IE0009355771.USD"],"gpt_icon":0},{"id":"2582289816","title":"New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2582289816","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582289816?lang=en_us&edition=fundamental","pubTime":"2025-11-10 05:15","pubTimestamp":1762722900,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Nov.  09, 2025  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a newpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/09/3184162/18362/en/New-REDUCE-IT-Aspirin-Analysis-Presented-at-AHA-Scientific-Sessions-2025-Reinforces-VASCEPA-VAZKEPA-Icosapent-Ethyl-Reduced-Cardiovascular-Events-in-High-Risk-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","CV","TG","BK4604","IPE","BK4161","BK4082","BK4153","BK4110","CSII","ARR","BK4139","BK4090"],"gpt_icon":1},{"id":"2582486504","title":"Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2582486504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582486504?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:30","pubTimestamp":1762619400,"startTime":"0","endTime":"0","summary":"Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and at","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184076/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-AHA-Scientific-Sessions-2025-on-the-Potential-of-MRT-8102-a-NEK7-directed-Molecular-Glue-Degrader-to-Treat-Cardiovascular-and-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","GLUE","BK4539","CSII","MRT","BK4082","BK4139"],"gpt_icon":0},{"id":"2581003731","title":"King-Friend Biochemical Pharmaceutical Passes Drug Consistency Evaluation for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2581003731","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581003731?lang=en_us&edition=fundamental","pubTime":"2025-11-07 17:50","pubTimestamp":1762509045,"startTime":"0","endTime":"0","summary":"Nanjing King-Friend Biochemical Pharmaceutical  passed China's medical products administrator's generic drug quality and efficacy consistency evaluation for nadroparin calcium injection.The drug is used to prevent and treat thrombosis and related cardiovascular conditions, according to a filing made on Friday with the Shanghai Stock Exchange.Shares of the pharmaceutical company closed 2% higher Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603707","BK0186","BK4082","CSII","BK0046"],"gpt_icon":0},{"id":"2581301330","title":"Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2581301330","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581301330?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:45","pubTimestamp":1762447500,"startTime":"0","endTime":"0","summary":"At the ObesityWeek, Novo Nordisk A/S  presented new findings from the STEP UP phase 3b trial.The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg dose of semaglutide compared to the 2.4 mg dose and a placebo for weight management in adults with obesity.It showed that Wegovy helps obese people lose an average of 21% of their body weight.The company on Thursday said Wegovy also enabled the participants to achieve treatment targets linked to a low risk of obesity-related complications.The results applied to both the approved semaglutide 2.4 mg dose and the investigational higher 7.2 mg dose.In the STEP UP sub-analysis, more people with obesity who received Wegovy achieved the target BMI of less than 27, as well as a waist-to-height ratio of less than 0.53.People treated with Wegovy who achieved both treatment targets reached healthy levels for two or more cardiovascular risk factors, including blood pressure, cholesterol, and blood sugar levels.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/06/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/06/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CSII","LU0154236417.USD","LU1093756168.USD","BK4081","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","BK4082","BK4007","EMA","BK4599","LU1093756325.SGD","BK4532","BK4588"],"gpt_icon":1},{"id":"2578677584","title":"Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578677584","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578677584?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:57","pubTimestamp":1761605845,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (($ALNY)) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is conducting a pivotal Phase 3 clin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylams-zenith-study-a-new-horizon-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylams-zenith-study-a-new-horizon-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","CSII"],"gpt_icon":0},{"id":"2578674033","title":"Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578674033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578674033?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:14","pubTimestamp":1761603292,"startTime":"0","endTime":"0","summary":"Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled A Phase 3 Randomi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-maridebart-cafraglutide-a-new-hope-for-cardiovascular-health?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-maridebart-cafraglutide-a-new-hope-for-cardiovascular-health?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1057294990.SGD","BK4599","LU1571399168.USD","LU0868494617.USD","BK4534","BK4588","IE00B2B36J28.USD","LU2242652126.USD","LU0058720904.USD","LU2089984988.USD","LU2468319806.SGD","BK4082","AMGN","BK4533","LU2112291526.USD","BK4566","BK4139","BK4585","LU1983299246.USD","BK4581","LU0320765992.SGD","CSII","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE0002141913.USD","SG9999001440.SGD","LU2242646821.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","LU0889565916.HKD","IE0009355771.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}